DUBLIN - Sept. 1, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the FDA approval of the Enlitesensor for use with iPro2 Professional Continuous Glucose Monitoring (CGM) system, a market-leading CGM system that enables healthcare providers to obtain a more complete picture of glucose control for the diabetes patients they treat. The Enlite sensor is a disposable glucose sensor that can be worn up to six days and provides better comfort.
Press Release| Newsroom | Medtronic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.